How are energy investors positioned?
Ashiya Mona, a director at Disc Medicine, Inc. (NASDAQ:IRON), sold shares of the company’s common stock in transactions dated March 24, 2025. The sales, reported in a recent SEC filing, involved a total of 5,738 shares sold at a price of $54.11 each, amounting to $310,483. The transaction occurred as the stock, currently trading at $52.49, shows significant volatility according to InvestingPro data. With a market capitalization of $1.82 billion, Disc Medicine maintains strong liquidity, as indicated by its impressive current ratio of 21.17.
Following these transactions, Mona’s indirect ownership, as detailed in the filing’s footnotes, reflects a remaining balance of shares held through various OrbiMed entities. The filing highlights the complex nature of ownership through entities like OrbiMed Private Investments VI, LP, OrbiMed Private Investments VIII, LP, and OrbiMed Genesis Master Fund, L.P., with OrbiMed Advisors LLC managing the voting and investment power through its management committee. For deeper insights into insider transactions and comprehensive financial analysis, InvestingPro subscribers can access detailed reports covering over 1,400 US stocks, including Disc Medicine.
The transactions underscore the ongoing activities of insiders at Disc Medicine, a pharmaceutical company based in Watertown, Massachusetts. According to InvestingPro analysis, the company maintains a "Fair" financial health score, with analysts maintaining a strong buy consensus and setting price targets significantly above current trading levels.
In other recent news, Disc Medicine has been the focus of several analyst updates. Cantor Fitzgerald maintained its Overweight rating with a price target of $99, reflecting confidence in the company’s financial model following a public offering that increased the number of shares. Scotiabank (TSX:BNS) raised its price target for Disc Medicine to $75, citing plans for a New Drug Application submission for bitopertin in 2025 and a strengthened financial position due to recent capital raises. TD Cowen initiated coverage with a Buy rating, highlighting the potential market opportunities for Disc Medicine’s treatments, particularly bitopertin and another drug, 0974, targeting myelofibrosis anemia. Stifel also increased its price target to $94, maintaining a Buy rating, and expressed optimism about the approval prospects for bitopertin, anticipating a commercial launch in 2026. These developments underscore the growing interest and varied expectations among analysts regarding Disc Medicine’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.